Panelists:
Wayne Doyle, PhD
Head of Scientific Platforms & Strategy
Eclipsebio
Panelist
Wayne Doyle, PhD
Wayne Doyle earned his PhD at UT Southwestern and completed his postdoctoral training at UC San Diego. He previously worked at Active Motif, where he led the bioinformatics team, supporting biopharma partners and developing analytical strategies for emerging technologies. He joined Eclipsebio in 2022 and now leads the development of the company’s integrative partnership platforms for RNA therapeutics, including AI-powered design and end-to-end mRNA characterization solutions.
Tina de los Reyes
Strategic Biopharma Development Specialist
Oxford Nanopore Technologies
Panelist
Tina de los Reyes
Tina de los Reyes is the strategic biopharma development specialist for the Western US. With over 10 years of commercial experience in NGS and a Masters in Biomedical diagnostics, she specializes in identifying and growing new market applications.
- Time:
RNA-based therapeutics demand high-resolution quality control to ensure safety, efficacy, and consistency.
In this GEN webinar, Wayne Doyle will showcase how Eclipsebio’s eMERGE platform leverages nanopore sequencing to directly measure critical quality attributes—including base identity, poly(A) tail length, RNA integrity, and secondary structure within lipid nanoparticles. Learn how integrating sequencing-driven insights across development and manufacturing can reduce risk and strengthen confidence as RNA programs advance toward the clinic. Key takeaways from the webinar are:
- How nanopore sequencing enables high-resolution measurement of critical quality attributes (CQAs), including base identity, poly(A) tail length, and RNA integrity.
- How Eclipsebio’s sequencing-first eMERGE platform integrates nanopore and complementary assays to characterize RNA quality, from sequence fidelity and fragmentation to structural features and impurity profiling.
- How embedding sequencing-driven quality analytics into development and manufacturing workflows strengthens product understanding, improves batch-to-batch consistency, and reduces risk across the RNA therapeutic lifecycle.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post De-Risking RNA Therapeutics with High-Resolution Sequencing appeared first on GEN – Genetic Engineering and Biotechnology News.
